ArticleThe Lancet regional health. Europe2026
The effect of HPV vaccination on precancerous lesions and invasive cervical cancer in a low-vaccination-coverage setting in Germany: a retrospective cohort analysis.
Article in The Lancet regional health. Europe, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: HPV vaccination coverage among 18-year-old women in Germany was 61% in 2024, despite the recommendation for girls since 2007. We assessed the association between HPV vaccination and risk of precancerous lesions and invasive cervical cancer in Bavaria, Germany's largest state. Methods: We conducted a retrospective cohort analysis of females born 1990-2005, covering 17 years of follow-up (2008-2024), using health claims and prescription data from the Bavarian Association of Statutory Health Insurance Physicians (KVB). Cumulative incidence of precancerous cervical lesions and invasive cervical cancer was estimated using the Kaplan-Meier method, and risks were estimated using Cox regression models. Analyses accounted for factors such as HPV vaccination status, age at vaccination, pre-vaccination contraceptive prescription, cervical cancer screening participation, and place of residence. Findings: Among 669,053 females, 33.76% (225,899/669,053) were fully vaccinated, 13.34% (89,268/669,053) partially vaccinated, and 52.89% (353,886/669,053) unvaccinated. 8965 precancerous lesions and 669 invasive cervical cancers were diagnosed in females aged 19-34 years. By age 34 years, cumulative incidence of precancerous lesions and invasive cervical cancer was 0.025 (95% CI: 0.020, 0.029) and 0.001 (95% CI: 0.001, 0.002) in fully vaccinated cohorts, and 0.041 (95% CI: 0.040, 0.043) and 0.004 (95% CI: 0.003, 0.004) in unvaccinated cohorts, respectively. Adjusted hazard ratios among fully vaccinated females were 0.48 (95% CI: 0.45, 0.52) for precancerous lesions and 0.35 (95% CI: 0.26, 0.47) for invasive cervical cancer. Interpretation: HPV vaccination is associated with a lower incidence of precancerous lesions and invasive cervical cancer. This is the first direct evidence of the effectiveness of the HPV vaccine in Germany. Funding: No external funding.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.